Division of General Internal Medicine & Geriatrics, Department of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR (DB, JR, XAL, NJS, HE); De Paul Treatment Centers, Portland, OR (JH); Division of Hospital Medicine, Department of Medicine, Oregon Health & Science University, Portland, OR (HE).
J Addict Med. 2022;16(2):e105-e111. doi: 10.1097/ADM.0000000000000864.
Patients with opioid use disorder (OUD) can initiate buprenorphine without requiring a withdrawal period through a low-dose (sometimes referred to as "micro-induction") approach. Although there is growing interest in low-dose buprenorphine initiation, current evidence is limited to case reports and small case series.
We performed a retrospective cohort study of patients with OUD seen by a hospital-based addiction medicine consult service who underwent low-dose buprenorphine initiation starting during hospital admission. We then integrated our practice-based experiences with results from the existing literature to create practice considerations.
Sixty-eight individuals underwent 72 low-dose buprenorphine initiations between July 2019 and July 2020. Reasons for low-dose versus standard buprenorphine initiation included co-occurring pain (91.7%), patient anxiety around the possibility of withdrawal (69.4%), history of precipitated withdrawal (9.7%), opioid withdrawal intolerance (6.9%), and other reason/not specified (18.1%). Of the 72 low-dose buprenorphine initiations, 50 (69.4%) were completed in the hospital, 9 (12.5%) transitioned to complete as an outpatient, and 13 (18.1%) were terminated early. We apply our experiences and findings from literature to recommendations for varied clinical scenarios, including acute illness, co-occurring pain, opioid withdrawal intolerance, transition from high dose methadone to buprenorphine, history of precipitated withdrawal, and rapid hospital discharge. We share a standard low-dose initiation protocol with potential modifications based on above scenarios.
Low-dose buprenorphine initiation offers a well-tolerated and versatile approach for hospitalized patients with OUD. We share lessons from our experiences and the literature, and provide practical considerations for providers.
阿片类药物使用障碍(OUD)患者可以通过低剂量(有时称为“微诱导”)方法开始使用丁丙诺啡,而无需戒断期。尽管对低剂量丁丙诺啡的起始使用越来越感兴趣,但目前的证据仅限于病例报告和小病例系列。
我们对在一家医院成瘾医学咨询服务就诊的 OUD 患者进行了一项回顾性队列研究,这些患者在住院期间开始接受低剂量丁丙诺啡治疗。然后,我们将基于实践的经验与现有文献的结果相结合,以制定实践注意事项。
2019 年 7 月至 2020 年 7 月期间,68 名患者共进行了 72 次低剂量丁丙诺啡起始治疗。与标准丁丙诺啡起始相比,低剂量丁丙诺啡起始的原因包括共病疼痛(91.7%)、患者对戒断可能性的焦虑(69.4%)、有过戒断发作史(9.7%)、阿片类药物戒断不耐受(6.9%)以及其他原因/未特指(18.1%)。72 次低剂量丁丙诺啡起始中,50 次(69.4%)在医院完成,9 次(12.5%)转为门诊完全治疗,13 次(18.1%)提前终止。我们应用经验和文献中的发现,针对各种临床情况提出建议,包括急性疾病、共病疼痛、阿片类药物戒断不耐受、从高剂量美沙酮转为丁丙诺啡、戒断发作史和快速出院。我们分享了一个标准的低剂量起始方案,并根据上述情况提供了潜在的修改。
低剂量丁丙诺啡起始治疗为住院 OUD 患者提供了一种耐受良好且用途广泛的方法。我们分享了从经验和文献中获得的教训,并为提供者提供了实用的注意事项。